Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: SPOR Networks in Chronic Disease - LOI

University of Calgary

$50,000.00

INFLAME - CanadIan Network For cLinicAl excellence in Mucosal disEase

EF 2014-15

Résumé
Asthma and Inflammatory Bowel Disease (IBD) are both chronic inflammatory conditions that affect children and adults and impose substantial morbidity, occasional mortality, and a heavy economic burden on individuals, populations, and health care systems. Indeed, these diseases combined affect some 3.2 million Canadians with an annual economic burden estimated at over $6.5 billion. Canada has among the highest rates of IBD and Asthma in the world. The gut and lungs represent the two most prominent mucosal surfaces where our immune system interfaces with the environment and our commensal microbiome. IBD and Asthma share similar pathogeneses as both diseases are characterised by inappropriate immune responses to environmental and microbial stimuli in genetically susceptible individuals. Canada has internationally acknowledged excellence in defining how genes cause disease, in the imaging and assessment of the mucosal immune system, in the study and manipulation of the microbiome and in measuring the impact of such technologies on clinical care. What has been lacking is the ability to translate these technologies into clinical care in order to improve clinical outcomes. What we propose is to advance four research themes consisting of personalized genetics, human immune imaging, microbiome analysis and manipulation and healthcare outcome assessments into clinical IBD and Asthma care using a technology hub-based approach and $47.5m of existing pan-Canadian network infrastructures in IBD and Asthma to facilitate wide-spread access. Our vision is to use these technologies to transform clinical decision-making paradigms into one in which the correct biological target is identified and treated in the correct individual at the correct time to restore mucosal balance between the immune system and the commensal microbiome resulting in long-term remission of inflammation and improved health.
Programme
SPOR Networks in Chronic Disease - LOI
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
323923
Name
Eksteen Johannes A
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Clinical
Prcname2
SPOR Networks in Chronic Disease
Projecttitle
INFLAME - CanadIan Network For cLinicAl excellence in Mucosal disEase
Programtype2
Operating Grants
Orgnameinp2
University of Calgary
Cihramount2
$50,000
Cihrequipment2
$0
Programname2
SPOR Networks in Chronic Disease - LOI
Keyworddelim
Advanced Mucosal Imaging; Asthma; Environment; Genomics; Health Economics And Outcomes; Inflammatory Bowel Disease; Microbiome; Personalised Medicine
Abstract
Asthma and Inflammatory Bowel Disease (IBD) are both chronic inflammatory conditions that affect children and adults and impose substantial morbidity, occasional mortality, and a heavy economic burden on individuals, populations, and health care systems. Indeed, these diseases combined affect some 3.2 million Canadians with an annual economic burden estimated at over $6.5 billion. Canada has among the highest rates of IBD and Asthma in the world. The gut and lungs represent the two most prominent mucosal surfaces where our immune system interfaces with the environment and our commensal microbiome. IBD and Asthma share similar pathogeneses as both diseases are characterised by inappropriate immune responses to environmental and microbial stimuli in genetically susceptible individuals. Canada has internationally acknowledged excellence in defining how genes cause disease, in the imaging and assessment of the mucosal immune system, in the study and manipulation of the microbiome and in measuring the impact of such technologies on clinical care. What has been lacking is the ability to translate these technologies into clinical care in order to improve clinical outcomes. What we propose is to advance four research themes consisting of personalized genetics, human immune imaging, microbiome analysis and manipulation and healthcare outcome assessments into clinical IBD and Asthma care using a technology hub-based approach and $47.5m of existing pan-Canadian network infrastructures in IBD and Asthma to facilitate wide-spread access. Our vision is to use these technologies to transform clinical decision-making paradigms into one in which the correct biological target is identified and treated in the correct individual at the correct time to restore mucosal balance between the immune system and the commensal microbiome resulting in long-term remission of inflammation and improved health.
Competitiondate
201501
Approvedterm2
1 yr 0 mth
Pinamesdelim
Eksteen, Johannes A; Chatigny, Elaine; Kubes, Paul; Rioux, John D; Surette, Michael G
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $50,000~ $0~